Nevro (NVRO) has an average hold rating and price target range of $49 to $95, according to analysts polled by Capital IQ. (MT Newswires covers equity,...
Nevro (NVRO) has an average hold rating among analysts, with a price target range of $64 to $150. (MT Newswires covers equity, commodity and economic...
Nevro (NVRO) has an average rating of hold and price targets ranging from $64 to $125, according to analysts polled by Capital IQ. (MT Newswires covers...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 1800 Bridge Parkway Redwood City, California 94065 |
| Phone | +1.650.251.0005 |
| Number of Employees | 804 |
| Recent SEC Filing | 06/17/2022 4 |
| Chairman, President & Chief Executive Officer | D. Keith Grossman |
| Chief Financial Officer | Roderick H. MacLeod |
| Chief Medical Officer | David Caraway |
| Vice President-Technical Operations | Christopher Christoforou |
| Price Open | $44.09 |
| Previous Close | $43.83 |
| 52 Week Range | $39.41 - 168.19 |
| Market Capitalization | $1.6 B |
| Shares Outstanding | 35.3 M |
| Sector | Health Technology |
| Industry | Medical Specialties | Next Earnings Announcement | 08/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.49 |
| Beta vs. S&P 500 | N/A |
| Revenue | $387.3 M |
| Net Profit Margin | -35.25% |
| Return on Equity | -44.57% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
